Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2022 Earnings Conference Call May 2, 2022 8:00 AM ET
Company Participants
Mark Jacobson - Chief Operating Officer
Herriot Tabuteau - Chief Executive Officer
Lori Englebert - Senior Vice President of Commercial and Business Development
Nick Pizzie - Chief Financial Officer
Amanda Jones - Senior Vice President, Clinical Development
Conference Call Participants
Charles Duncan - Cantor Fitzgerald
Joon Lee - Truist Securities
Vikram Purohit - Morgan Stanley
Marc Goodman - SVB Leerink
Vamil Divan - Mizuho Securities
Joseph Thome - Cowen & Company
Ram Selvaraju - H.C. Wainwright
Jason Gerberry - Bank of America
Yatin Suneja - Guggenheim
Chris Howerton - Jefferies
Matt Kaplan - Ladenburg Thalmann
Bert Hazlett - BTIG
Myles Minter - William Blair
David Hoang - SMBC
Esther Hong - Berenberg
Operator
Good morning, and welcome to the Axsome Therapeutics Conference Call. Currently, all participants are in a listen-only mode. Later, there will be a question-and-answer session and instructions will follow at that time. As a reminder, today's conference call is being recorded.
I would now like to turn the conference over to your host, Mark Jacobson, Chief Operating Officer at Axsome Therapeutics. Please go ahead.
Mark Jacobson
Thank you, operator. Good morning, and thank you all for joining us on today's conference call. This morning, we issued two press releases. Our earnings press release providing a corporate update and details of the company's financial results for the first quarter of 2022 and the release relating to the FDA's action on the AXS-07 NDA. These crossed the wire a short time ago and are available on our website at axsome.com.
During today's call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our investigational agents, our clinical and non-clinical plans, our plans to present or report additional data, the anticipated conduct and the source of future clinical trials, regulatory plans, future research and development plans, commercial plans and possible intended use of cash and investments. These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the Securities and Exchange Commission, including our quarterly and annual reports. You are cautioned us to place undue reliance on these forward-looking statements, which are only made as of today's date, and the company disclaims any obligation to update such statements.